What is Leerink Partnrs’ Estimate for CRSP Q1 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($1.33) per share for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($1.26) EPS, Q4 2025 earnings at ($1.26) EPS and FY2026 earnings at ($5.17) EPS.

CRSP has been the topic of several other research reports. HC Wainwright assumed coverage on CRISPR Therapeutics in a research note on Monday, February 3rd. They set a “buy” rating and a $65.00 price objective on the stock. Royal Bank of Canada cut their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a report on Wednesday. TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research report on Wednesday. Chardan Capital restated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and an average price target of $76.11.

CRISPR Therapeutics Trading Up 9.3 %

CRSP opened at $43.30 on Thursday. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10. The firm’s fifty day moving average is $42.06 and its two-hundred day moving average is $46.25.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Capital Market Strategies LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $461,000. KBC Group NV lifted its holdings in CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock valued at $2,382,000 after purchasing an additional 57,696 shares during the last quarter. Capital Advisors Inc. OK boosted its position in CRISPR Therapeutics by 8.1% during the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after purchasing an additional 22,583 shares during the period. Geode Capital Management LLC boosted its position in CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after purchasing an additional 35,196 shares during the period. Finally, State Street Corp increased its holdings in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.